Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...
"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...
The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries ...
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...
in Europe The partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategy TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International ...
Teva Pharmaceuticals International GmbH, a subsidiary of Teva, has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, ...
Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...
Harel Insurance Investments and Financial Services Ltd. (TASE: HARL) rose 4.59% for the biggest rise on the Tel Aviv 35 Index today and Phoenix Finance (TASE: PHOE) rose 2.38%. ICL (TASE: ICL: NYSE: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback